No Data
A Quick Look at Today's Ratings for Intellia Therapeutics(NTLA.US), With a Forecast Between $60 to $90
Positive Buy Rating for Intellia Therapeutics Amid Promising Trial Results for Nex-z in ATTR-CM
Intellia Therapeutics Price Target Lowered to $70 From $80 at Wells Fargo
Intellia Therapeutics' NTLA-2001 Shows Promising Potential With Positive Phase 1 Data and Accelerated Phase 3 Enrollment
Intellia Therapeutics Is Maintained at Overweight by Wells Fargo
Intellia Therapeutics Price Target Maintained With a $14.00/Share by Wedbush
No Data
No Data
